(2-Methoxyethyl)({1-[(oxolan-3-yl)methyl]-1H-1,2,3-triazol-4-yl}methylidene)amine

Catalog No. :
ACANTC812
CAS No. :
2060523-33-1
Molecular Formula :
C11H18N4O2
Molecular Weight :
238.29

IUPAC Name:(Z)-N-(2-methoxyethyl)-1-(1-((tetrahydrofuran-3-yl)methyl)-1H-1,2,3-triazol-4-yl)methanimine

(2-Methoxyethyl)({1-[(oxolan-3-yl)methyl]-1H-1,2,3-triazol-4-yl}methylidene)amine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$633.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(2-Methoxyethyl)({1-[(oxolan-3-yl)methyl]-1H-1,2,3-triazol-4-yl}methylidene)amine
IUPAC Name(Z)-N-(2-methoxyethyl)-1-(1-((tetrahydrofuran-3-yl)methyl)-1H-1,2,3-triazol-4-yl)methanimine
MDL No.MFCD30500879
Molecular FormulaC11H18N4O2
Molecular Weight238.29
SMILESCOCC/N=C\C1=CN(CC2COCC2)N=N1
InChI KeyFJMROQBHEITWHH-SDQBBNPISA-N
SynonymEthanamine, 2-methoxy-N-[[1-[(tetrahydro-3-furanyl)methyl]-1H-1,2,3-triazol-4-yl]methylene]-
CAS No.2060523-33-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACANTC812 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACWAKZ917 route compound structure diagram
    ACWAKZ917663941-77-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACANTC812 route product structure diagram
    ACANTC8122060523-33-1
Inquiry

2. ACANTC812 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACANTC812 route product structure diagram
    ACANTC8122060523-33-1
Inquiry

Comments (0)